Broncus Medical-B (02216) witnessed an intraday surge exceeding 12%, trading at HK$2.29 by press time—an 11.17% increase—with turnover reaching HK$27.34 million. This momentum follows the company's announcement that its BroncAblate pulmonary radiofrequency ablation system has officially commenced commercialization.

Earlier developments paved the way for this milestone: In April, Broncus secured approval for its disposable BroncAblate ablation catheter. Subsequently, June brought regulatory clearance from China's NMPA for the BroncAblate console. These approvals collectively enable the full commercial rollout of BroncAblate—the world’s first transbronchial radiofrequency ablation device for lung cancer treatment.

Huatai Securities highlighted Broncus’s expanding pipeline in a recent research note. The RF-II lung cancer therapy, having released pre-market clinical trial results in August 2024, is anticipated to launch domestically in 2025. Meanwhile, the TLD device targeting COPD treatment completed patient enrollment across 20+ hospitals by late 2024, with full follow-up expected by 2026. The transbronchial flexible surgical robot remains in preliminary research phases.